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Abstract
Background: There is a general lack of information on the care of inflammatory bowel disease
(IBD) in a broad, geographically diverse, non-clinic population. The purposes of this study were (1)
to compare a sample drawn from the membership of a national Crohn's and Colitis Foundation to
published clinic-based and population-based IBD samples, (2) to describe current patterns of health
care use, and (3) to determine if unexpected variations exist in how and by whom IBD is treated.
Methods: Mailed survey of 4453 members of the Crohn's and Colitis Foundation of Canada. The
questionnaire, in members stated language of preference, included items on demographic and
disease characteristics, general health behaviors and current and past IBD treatment. Each member
received an initial and one reminder mailing.
Results: Questionnaires were returned by 1787, 913, and 128 people with Crohn's disease,
ulcerative colitis and indeterminate colitis, respectively. At least one operation had been performed
on 1159 Crohn's disease patients, with risk increasing with duration of disease. Regional variation
in surgical rates in ulcerative colitis patients was identified. 6-Mercaptopurine/Azathioprine was
used by 24% of patients with Crohn's disease and 12% of patients with ulcerative colitis (95% CI
for the difference: 8.9% – 15%). In patients with Crohn's disease, use was not associated with
gender, income or region of residence but was associated with age and markers of disease activity.
Infliximab was used by 112 respondents (4%), the majority of whom had Crohn's disease. Variations
in infliximab use based on region of residence and income were not seen. Sixty-eight percent of
respondents indicated that they depended most on a gastroenterologist for their IBD care. There
was significant regional variation in this. However, satisfaction with primary physician did not
depend on physician type (for example, gastroenterologist versus general practitioner).
Conclusion: This study achieved the goal of obtaining a large, geographically diverse sample that
is more representative of the general IBD population than a clinic sample would have been. We
could find no evidence of significant regional variation in medical treatments due to gender, region
of residence or income level. Differences were noted between different age groups, which deserves
further attention.
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Background
In 2001, we conducted a national survey of the members
of the Crohn's and Colitis Foundation of Canada. The pri-
mary objective of the survey was to examine the use of
complementary and alternative medicine by people with
inflammatory bowel disease (IBD) (Am J Gastro in press).
The secondary objectives were (1) to compare responding
members to published clinic-based and population-based
IBD samples, (2) to describe current patterns of health
care and behaviors of IBD patients and (3) to determine if
unexpected variations exist in how and by whom IBD is
treated in Canada.
There is a general lack of information on the care of IBD
in a broad, geographically diverse, non-clinic-based pop-
ulation of patients. In the absence of defined population-
based cohorts of IBD patients, investigators tend to rely on
clinic samples when conducting surveys on a variety of
issues. Often these published patient cohorts are derived
from specialty centers. Clinic samples are clearly limited
in that they would be expected to include the sickest
patients and those who seek care through conventional
medical providers. For our study of complementary and
alternative medicine use, we believed that such as sample
was inappropriate. In North America identifying a popu-
lation-based IBD sample is difficult, if not impossible, in
most jurisdictions. Therefore, we approached the Crohn's
and Colitis Foundation of Canada to conduct a survey of
their membership. We believed that this would be a rea-
sonable approach to obtaining a sample, that although
not truly population-based, would be large and geograph-
ically diverse and that would include patients that might
be missed or underrepresented in clinic-based samples.
Medical and surgical care should depend predominantly
on the health care needs of the patient. However, there are
many examples where variations in health care cannot be
explained by the health care needs of the population, but
instead are associated with characteristics of the patients,
such as age, gender, income level or place of residence.[1]
Canada has a predominantly publicly-financed, privately-
delivered health care system. The public health care insur-
ance program provides access to universal, comprehensive
coverage for medically necessary hospital, in-patient and
outpatient physician services. However, this program does
not cover the costs of outpatient medications. Outpatient
medications are paid for out of pocket and by separate
public and private insurance programs.
When examining the predictors of and variations in the
treatment of IBD, we have focused on surgery, 6-Mercap-
topurine/azathioprine (6 MP/Aza) and infliximab use in
patients with Crohn's disease and the type of physician
providing primary IBD care. It is unlikely that anyone
would dispute that corticosteroids are appropriate and
effective drugs for treating patients with moderate-severe
disease activity. In contrast, despite the fact that 6 MP/Aza
is one of the oldest treatments for Crohn's disease and was
included in the National Cooperative Crohn's Disease
Study [2], concern about the potential for long-term side
effects, prolonged time to therapeutic onset and true effec-
tiveness may result in less consensus as to its role and,
therefore, greater variation in its use for the treatment of
Crohn's disease patients. The use of 6 MP/Aza in ulcera-
tive colitis is less established than in Crohn's disease. Inf-
liximab is a new therapeutic agent that was progressing
through clinical trials and just entering clinical practice at
the time of this survey.
Methods
Study Sample
All members of the Crohn's and Colitis Foundation of
Canada (CCFC) were eligible to participate. The CCFC
sent a letter to each of the 5146 members on its mailing
list asking them to respond if they did not wish their name
and address to be provided on a one-time basis to Univer-
sity affiliated researchers conducting a survey. Approxi-
mately 458 people declined to be contacted, of whom it is
believed approximately 20% were physician or corporate
members. The CCFC then provided to us a mailing list
that excluded these individuals. Our mailing list included
4688 individuals (language preference: English 4074,
French 614). A random sample of 235 people was selected
for two pilot studies and the remaining 4453 were
included in the main postal survey.
Membership in the CCFC requires a $30 annual member-
ship fee.[3] The primary purpose of the CCFC is to "Find
the Cure" through fund-raising and supporting research.
Local educational events are held, but the CCFC does not
organize support groups as part of its mandate. Members
are sent regular mailings by the CCFC about recent
research and local educational events.
Survey Methodology
The package mailed to the main study sample was in the
member's stated language preference. It included a cover
letter from the investigators, a self-addressed, stamped
return envelope and adult and pediatric versions of the
questionnaire. The cover letter indicated that the ques-
tionnaire was to be completed by the addressee (the CCFC
member) unless that person did not have IBD. If that per-
son did not have IBD but one of their children less than
age 16 did, they were asked to complete the pediatric
questionnaire. They were asked to indicate on the ques-
tionnaire that they did not have IBD if neither of these
conditions were met and to return the questionnaire oth-
erwise uncompleted. The first set of questionnaires was
mailed in September and October 2001. A secondBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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questionnaire was sent to non-respondents approxi-
mately 8 weeks later.
In a pilot study we contacted by telephone 159 CCFC
members of whom 152 (96%) agreed to participate in an
interview. Twenty-eight (18%) of the contacted members
did not have inflammatory bowel disease. Of these, 22
(79%) had a family member with IBD, of which 3 indi-
cated that the family member was under age 16 and resid-
ing in the same household. Based on these results, we
would have expected that 16% of the membership
selected for the mailed survey would not have been eligi-
ble and should have returned their questionnaires
uncompleted and marked as "do not have IBD".
Instrument design and testing
A draft questionnaire was created based on our previous
surveys and other published surveys of complementary
medicine use.[4–8] Versions for adults (age 16 and above)
and children were created. Only the results from the adult
questionnaire are provided in this paper. The adult ver-
sion included items on the nature of the member's IBD,
past and current medical treatments, disease-related con-
cerns, complementary medicine use, reasons for comple-
mentary medicine use or non-use, other general health
attitudes and behaviors, and demographic characteristics.
We have previously found substantial agreement between
patients self-report and GI clinic chart reviews for medica-
tions such as azathioprine and oral corticosteroids.[9]
Current IBD disease activity was measured using a single
item on self-assessed global activity (How would you rate
the activity of your IBD today?) with a 7-point Likert scale
that ranged from "totally inactive" to "terrible, worse that
it has ever been". For this analysis activity was collapsed
into four categories (Inactive = Inactive, Slight = Mild,
Some/Moderate=Moderate and Quite/Extreme/Terri-
ble=Severe).
A patient's preferred role in the treatment of their IBD was
with a single 5-item question, that ranged from "I prefer
to make the final selection about which treatment I will
receive" to "I prefer to leave all decisions regarding my
treatment to my doctor."
Prior to pilot testing, the draft questionnaire was reviewed
by several IBD experts. Pilot testing of the adult English
version of the questionnaire was conducted in two cities
(Vancouver, Calgary) on a total sample of 74 patients
recruited through gastroenterology clinics. One translator
translated the original English questionnaire into French.
The French translation was pilot tested in Montreal on 31
French-speaking patients recruited through an IBD clinic.
The questions were then revised and checked a second
time for meaning and grammar by a second translator.
Analysis
Each variable was initially described using descriptive sta-
tistics (means, standard deviations, proportions) and
graphs. The strength of association between two variables
was measured using odds ratios and 95% confidence
intervals. Demonstrating statistical significance was based
on 95% confidence intervals that did not cross unity or a
P value ≤ 0.05. P values were calculated by t tests or chi
square tests as appropriate. Logistic regression was used to
estimate confidence intervals and P values for factors that
had more than two levels and to examine for potential
confounding and interaction.
Ethical Considerations
The study was approved by the Conjoint Health Research
Ethics Board at the University of Calgary.
Results
Respondents
Questionnaire packages were mailed to 4453 CCFC mem-
bers. Packages were returned due to wrong addresses for
101 members. Questionnaires were returned by 3284
members (response rate 75.5%). We excluded 437
responses from the final analysis sample because the
member did not have IBD (n = 310, 9% of returned ques-
tionnaires), the majority of the questionnaire was not
completed (n = 24), member deceased (n = 8), residence
out of Canada (n = 17) or type of IBD not given (n = 6).
The demographic characteristics of the analysis sample are
shown in Table 1.
Disease Characteristics
The number (%) of patients who classified themselves as
having Crohn's disease, ulcerative colitis or indeterminate
colitis/unclear disease type were 1787 (63%), 913 (32%)
and 128 (5%), respectively. Because of the small number
in the indeterminate colitis/unclear group, subsequent
subgroup analyses based on disease type are performed
only on those with Crohn's disease or ulcerative colitis.
Disease characteristics of those with Crohn's disease and
ulcerative colitis are shown in Table 2.
Disease activity was rated as inactive by 19% of CD
patients and 27% of UC patients (P < 0.001). In those
with CD, no statistically significant difference in disease
activity was seen among men or women or among the dif-
ferent age groups. Among those with ulcerative colitis,
inactive disease was much more likely to be reported
among those who had previously undergone surgery than
those who had not (55% vs. 22%, P < 0.001). Although
we did not specifically ask patients what kind of surgery
they had undergone, we presume that the procedure in
the majority of patients with ulcerative colitis was total
proctocolectomy with or without ileal pouch formation.
After considering whether or not the UC patient hadBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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undergone surgery, age and sex were not associated with
the likelihood of having inactive disease.
Surgical Therapy
At least one operation had been performed on 1159
(64.9%) patients with Crohn's disease and 142 (15.6%)
patients with ulcerative colitis. For patients with Crohn's
disease and ulcerative colitis, the probability of having
undergone at least one surgery was associated with the
number of years since their diagnosis (Table 3). A non-lin-
ear trend was seen in those with UC between the likeli-
hood of having undergone surgery and age. Twelve
percent of those in the 16 – 24 year age group had under-
gone surgery, compared with 17% in the two age groups
25 – 40 and 41 – 55. However, those over age 55 had a
similar 12% surgery rate as those in the youngest age
group. However, these differences were not statistically
significant.
Overall, 16% of ulcerative colitis patients had undergone
an operation for their disease. Although we did not specif-
ically ask patients what kind of surgery they had under-
gone, we presume that the majority of patients had
undergone total proctocolectomy with or without ileal
pouch formation. There was evidence that the probability
of having had surgery varied with the geographic region
that the patient lived (P = 0.001). Table 4 shows factors
associated with prior surgery in UC patients. Only dura-
tion of disease and geographic region were significant pre-
dictors of prior surgery.
Medical Treatment
The medical treatments received by patients with Crohn's
disease and ulcerative colitis over the preceding twelve
months are shown in Table 5.
6 MP/Aza was used by 24% of patients with Crohn's dis-
ease and 12% of patients with ulcerative colitis (95% CI
for the difference: 8.9–15%, p < 0.001). Table 6 shows fac-
tors associated with 6 MP/Aza use in Crohn's disease
patients. In those with CD, gender, income and region of
residence were not associated with the use of 6 MP/Aza.
However, their use was associated with age and markers of
more active disease (use of either oral or intravenous ster-
oids in the past 12 months, surgery within the past 2 years
and number of hospitalizations in the past 5 years). The
association between older age and less use of 6 MP/Aza
persisted after adjustment for disease activity.
Because of the relatively small number of UC patients
who had used 6 MP/Aza in the past 12 months, we did not
attempt to examine multiple predictors of its use. How-
ever, in those patients who had not had previous surgery,
we could find no evidence that 6 MP/Aza use varied by
gender or region of residence. As with Crohn's disease,
younger patients were more likely to report its use (e.g.
30% of those 16 – 24 and 10% of those over age 55, P =
0.011).
Infliximab had been used by 112 (4.0%) respondents.
The majority of patients who had received Infliximab
were in the Crohn's disease group, but 7 (1.0%) with
ulcerative colitis and 6 (4.7%) with indeterminate colitis
also reported its use. Associations between the use of Inf-
liximab and specific patient, disease and treatment charac-
teristics are shown in Table 7. Significant differences in the
proportion of patients who had received Infliximab were
not seen across income levels or across the five geographic
regions.
General IBD Health Care
Sixty eight percent of respondents with Crohn's disease or
ulcerative colitis indicated that they depended most on a
gastroenterologist for their IBD. There was significant
regional variation in this, in that 74% of patient in
Ontario or Quebec depended most on a gastroenterolo-
Table 1: Demographic characteristics of IBD sample
Characteristic
Age, mean (range) 47 years (16 – 88)
Females, n (%) 1729 (61%)
Region, n (%)
Maritime Provinces 155 (6%)
Quebec 464 (16%)
Ontario 1307 (46%)
Prairies (Alberta, Saskatchewan, Manitoba) 636 (23%)
West Coast (British Columbia, Territories) 266 (9%)
Education, n (%)
Less than high school diploma 268 (10%)
High school diploma 482 (17%)
Technical college or some university course 990 (35%)
University degree 1046 (38%)
Employment status, n (%)
Employed 1814 (64%)
Student 148 (5%)
Homemaker 266 (9%)
Unable to be employed due to illness 220 (8%)
Retired 481 (17%)
Other unemployed† 62 (2%)
Combined family pre-tax income, n (%)
<$20 K 174 (6%)
21–40 K 444 (16%)
41–60 K 474 (17%)
61–80 K 423 (15%)
>80 K 759 (27%)
Did not answer 552 (19%)
Born in Canada, n (%) 2548 (91%)
†For employment status, other unemployed includes never employed 
and unemployed not due to IBDBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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gist compared with 55–61% of patients in the rest of the
country.
Seventy-two percent of respondents indicated they were
"a lot" or "completely" satisfied with the care they
received when they last saw the doctor they depended on
most. There was no significant difference in degree of sat-
isfaction between those who relied most on a gastroenter-
ologist and those who did not.
Patients were asked what role they wished to play in the
treatment of their IBD. The largest proportion (44%) pre-
ferred that they shared responsibility with their physician
for treatments decisions. This was the case for all age
groups except among patients 16–24 years, the largest
proportion (42%) of this age group preferred to make
their own final treatment decision after seriously consid-
ering their doctor's opinion. In contrast, patients in the
older age groups relied more upon their physicians to
make their treatment decisions for them. Of those over
age 55, 33.0% indicated that they preferred their doctor to
make treatment decisions compared with only 13% –
17% in the other age groups.
Discussion
In this paper, we have reported on one of the largest pub-
lished surveys of patients with inflammatory bowel dis-
ease. The sample was drawn from the membership of the
Crohn's and Colitis Foundation of Canada. The primary
strengths of our sample are that it is (1) very large, (2) geo-
graphically diverse, (3) diverse in terms of patient and dis-
ease characteristics and (4) non-clinic based. However, it
is not a true population-based sample, which would be
most desirable for obtaining unbiased results. How repre-
sentative our sample is of the general IBD population
(freedom from bias) will be affected by who chooses to
join the CCFC and who chose to complete the question-
naire. We would have expected from our pilot study that
16% of respondents would have indicated that they did
not have IBD. However, only 9% of questionnaires were
returned with this indicated. This suggests that those who
did not have IBD were less likely to respond to the ques-
tionnaire than those with IBD.
In our study we did not validate the respondents' diagno-
sis of IBD. We did exclude anyone who did not classify
themselves into one of our three categories of IBD (We
also excluded anyone who wrote in another form of coli-
tis, such as collagenous colitis). A study of Crohn's and
Table 2: Disease and treatment characteristics of respondents with Crohn's disease and Ulcerative colitis
Characteristic Crohn's disease Ulcerative colitis 95% CI for difference (P value)
Disease duration, mean (± SD) 18.4 years (10.7) 14.8 years (9.8) 2.8 to 4.4 (<0.001)
Ever hospitalized, n (%) 1494 (83.6%) 464 (50.8%) 29.1 to 36.5% (<0.001)
Number of hospitalizations past 5 years, mean (± SD) 2.7 (3.0) 1.9 (1.9) 0.5 to 1.1 (<0.001)
Ever surgery, n (%) 1159 (64.9%) 142 (15.6%) 46.1 to 52.5% (<0.001)
Surgery within the past 2 years 255 (14.3%) 44 (4.8%) 7.3 to 11.6% (<0.001)
Disease Activity, n (%)
Inactive 329 (18.4%) 241 (26.4%) -11.4 to -0.6% (<0.001)
Mild 607 (34.0%) 299 (32.8%) -2.5 to 5.0% (0.547)
Moderate 616 (34.5%) 268 (29.4%) 1.4 to 8.8% (0.007)
Severe 204 (11.4%) 82 (8.9%) 0.1 to 4.8% (0.055)
Table 3: Percentage of patients with Crohn's disease and ulcerative colitis that reported having had at least one surgery by time since 
diagnosis
Crohn's disease n (%) Ulcerative Colitis n (%)
Years since diagnosis
0 – 2 6 (22%) 2 (8%)
3 – 5 76 (39%) 11 (9%)
6 – 10 170 (51%) 35 (17%)
11 – 20 398 (65%) 47 (14%)
21 – 30 350 (83%) 31 (19%)
>30 157 (84%) 16 (25%)BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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Colitis Foundation of America members in North Caro-
lina found that 98% of members who self-reported IBD
were judged to have definite or probable disease based on
clinical assessment of x-ray, endoscopy or pathology
reports.[10] Examining the drug and health care experi-
ences provides some further validation of our sample.
Only 637 (23%) had not used at least one IBD drug ther-
apy in the past 12 months (excluding antidiarrheals, anti-
biotics and narcotics). Of these, only 199 (7% of total
sample) had not undergone at least one surgery for their
IBD. Finally, 94 of the 199 (3% of total sample) had never
been hospitalized because of their disease. Therefore, we
are confident that our sample is not significantly contam-
inated by people who do not have IBD. We have also pre-
viously found that there was a high degree of agreement
between patient self-classification as to disease type and
that recorded in their medical charts.[9]
To better understand how our sample relates to both the
larger IBD population and to clinic-based samples, we
compared demographic and disease characteristics of this
sample to two other published samples.
First, we have previously published on the CAM use of a
gastroenterology-clinic based IBD sample.[4] In compari-
son to that sample, our current sample is slightly older
(mean age 46 vs. 40 years), contains fewer females (61%
vs. 68%) and is better educated (73% vs. 64% with educa-
tion beyond high-school degree). However, as expected,
the current sample also contains more people with less
severe Crohn's disease as shown by lower rate of hospital-
izations (83% vs. 92%) and surgery (65% vs. 79%) and,
although measured in different ways in the two studies,
probably less use of oral and iv corticosteroids. In con-
trast, the ulcerative colitis sample includes a larger propor-
tion of patients who have undergone surgery (presumably
proctocolectomy 16% vs. 6%).
The second comparison is the population-based sample
from the University of Manitoba IBD Database.[11–13]
Our current sample is also older than this population and
is especially underrepresented by patients in the 20 – 29
year old age group. Our sample also has a larger propor-
tion of females and a higher education level than the
Manitoba sample, although employment levels appear
roughly similar. The higher socioeconomic status of our
sample could reflect that this group is more interested in
membership and/or could also be the result of the very
modest annual membership fee limiting access to those of
lesser means. Finally, the Manitoba sample classified
patients as Crohn's disease or ulcerative colitis only, with
a ratio of 1.17 Crohn's disease patients to ulcerative colitis
patients. In our sample, we had nearly twice the number
of people identifying themselves as having Crohn's dis-
ease versus ulcerative colitis.
Therefore, there are important differences between our
sample and two other IBD populations. First, as desired,
our current sample does appear to include a broader range
of patients, especially in terms of patients with less severe
disease or UC patients who have previously undergone
surgery, than our clinic-based sample. However, in con-
trast to a population-based sample, our current sample is
older, contains a greater proportion of females and those
with Crohn's disease, and is better educated. These differ-
ences probably are the result of self-selection into the
CCFC membership rather than due to who chose to
respond to our questionnaire. The proportion of non-
respondents who had a female title (i.e. Mrs. Ms.) in the
CCFC mailing list was similar to the proportion of
females in our analysis sample.
Based on these comparisons, we believe that this sample
achieved our goal of obtaining a large, geographically
diverse sample, which although not necessarily fully rep-
resentative of the general IBD population, is likely more
so than more readily available clinic samples. Creating a
national sample for a mailed survey using the methodol-
ogy of the Manitoba IBD cohort clearly would have been
a daunting, if not impossible, task. Biased prevalence esti-
mates of parameters of interest could be derived from our
sample if they were associated with sex, age or educational
achievement. However, these limitations can be acknowl-
edged and potentially minimized through stratified anal-
ysis or standardization.
One aspect of quality of medical care is access to appropri-
ate treatments. Most previous studies of physician practice
Table 4: Associations between the previous surgery and patient 
characteristics for patients with ulcerative colitis
Characteristics % Reporting
Surgery
Odds ratio† 95% CI†
Sex
Male 15.2 Referent
Female 15.8 1.0 0.7 – 1.5
Age
16–24 11.8 Referent
25–40 17.5 1.2 0.4 – 3.9
41–55 16.8 1.0 0.3 – 3.0
>55 15.0 0.6 0.2 – 1.9
Region
Maritimes 8.3 Referent
Quebec 11.3 1.5 0.5 – 4.6
Ontario 16.0 2.1 0.7 – 6.0
Prairies 24.4 3.5 1.2 – 10.4
West Coast 7.6 0.9 0.2 – 3.3
† Adjusted for duration of diseaseBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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Table 5: Treatment characteristics of respondents with Crohn's disease and Ulcerative colitis.
Treatments CD n (%) UC n (%) 95% CI for difference (P value)
PO 5ASA 956 (54%) 672 (74%) -23.7 to -16.4 (<0.001)
Topical Steroids/5ASA 183 (10%) 391 (43%) -36.1 to -29.1 (<0.001)
PO Steroids 623 (35%) 259 (28%) 2.8 to 10.2 (0.001)
6 MP/Azathioprine 424 (24%) 109 (12%) 8.9 to 14.7 (<0.001)
IV Steroids 90 (5%) 41 (5%) -1.1 to 2.2 (0.571)
Infliximab 99 (6%) 7 (1%) 3.6 to 6.0 (<0.001)
PO: Per os 5ASA: 5-Aminosalicylates 6MP: 6-Mercaptopurince IV: Intravenous
Table 6: Associations between the use of Azathioprine or 6-mercaptopurine and patient and treatment characteristics for patients with 
Crohn's disease
Characteristics % reporting Aza/6 MP Odds ratio 95% CI
Sex
Male 23.5 Referent
Female 23.8 1.0 0.8 to 1.3
Age
16–24 45.3 Referent
25–40 29.0 0.5 0.3 to 0.8
41–55 22.3 0.4 0.2 to 0.6
>55 15.0 0.2 0.1 to 0.4
Disease activity
Inactive 19.2 Referent
Mild 18.5 1.0 0.7 to1.3
Moderate 26.6 1.5 1.1 to 2.1
Severe 38.2 2.6 1.7 to 3.9
Hospitalizations Past 5 Years
None 17.4 Referent
1 – 2 26.1 1.7 1.3 to 2.2
> 2 38.8 3.0 2.2 to 4.1
Surgery within the past 2 years
No 21.3 Referent
Yes 38.0 2.3 1.7 to 3.0
IV Steroids in past 12 months
No 22.8 Referent
Yes 41.1 2.4 1.5 to 3.7
PO Steroids in past 12 months
No 16.6 Referent
Yes 37.1 3.0 2.4 to 3.7
Combined family income before taxes ($)
< 20,000 27.6 Referent
21,000–40,000 18.8 0.6 0.4 to1.0
41,000–60,000 24.7 0.9 0.5 to1.4
61,000–80,000 26.9 0.9 0.6 to 1.6
> 80,000 25.5 0.9 0.6 to 1.4
Prefer not to answer 21.4 0.7 0.4 to 1.2
Region
Maritimes 21.0 Referent
Quebec 28.2 1.5 0.9 to 2.5
Ontario 23.6 1.2 0.7 to 1.9
Prairies 22.0 1.1 0.6 to 1.8
West Coast 22.6 1.1 0.6 to 2.0BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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patterns in IBD have been of members of specialty socie-
ties or IBD organizations and have relied on physician
self-report.[14–16]
In general we could find no evidence of significant varia-
tions in medical treatments due to gender, region of resi-
dence or income level. We did see differences associated
with age. In general older patients were less likely to have
received common IBD medical treatments in the preced-
ing 12 months although they reported similar levels of
disease activity.
Immunosuppressive drugs, predominantly the purine
analogs, have become increasingly emphasized in the
treatment of Crohn's disease as a way to reduce corticos-
teroid exposure, maintain remission and alter the natural
history of the disease.[17] We found that 24% of Crohn's
disease patients reported the use of azathioprine or 6-mer-
captopurine in the previous 12 months. There is limited
data on immunosuppressive use in IBD populations. Fea-
gan et al. reported that 5% of patients with a Crohn's-
related medical claim in several United States employee
health plans had used 6 MP/Aza over a 1-year period from
1994–1995.[18] Metge et al. reported that 9% of the
patients in the University of Manitoba IBD database who
received at least one pharmaceutical prescription in 1997
filled a prescription for an immunosuppressive agent.[12]
Although the populations and measures of 6 MP/Aza use
differ between the studies, our data combined with these
published studies does support a growing use of immuno-
suppressive drugs in Crohn's disease. Consistent with the
generally accepted indications for immunosuppressive
use, we found greater 6 MP/Azathioprine use by those
who had used intravenous or oral corticosteroids in the
past 12 months, those with multiple hospitalizations in
the past five years and those who had undergone surgery
within the past two years. Metge et al. reported that men
were more likely to receive immunosuppressives than
women.[12] However, we found no difference, even when
examining the age groups that would include women of
child-bearing age.
Infliximab entered clinical trials in Canada in mid-1999.
A compassionate release program was instituted in the
fourth quarter of 1999 and ran until the drug was given
approval by the Health Protection Branch in June 2001.
Table 7: Associations between the use of infliximab and patient, disease and treatment characteristics for patients with Crohn's disease 
(n = 1787)
Characteristics % Reporting Infliximab Odds ratio 95% CI
Sex
Male 5.5 Referent
Female 5.6 1.0 0.7 to 1.6
Age
16–24 11.6 Referent
25–40 7.7 0.6 0.3 to 1.3
41–55 4.8 0.4 0.2 to 0.8
>55 2.7 0.2 0.1 to 0.5
Disease activity
Inactive 1.8 Referent
Mild 2.3 1.3 0.5 to 3.3
Moderate 5.4 3.0 1.3 to 7.4
Severe 21.1 14.4 5.7 to 36.3
Prior hospitalization
No 1.7 Referent
Yes 6.3 3.9 1.6 to 9.6
Surgery within the past 2 years
No 4.6 Referent
Yes 11.4 2.7 1.7 to 4.2
IV Steroids in past 12 months
No 4.8 Referent
Yes 18.9 4.6 2.6 to 8.2
PO Steroids in past 12 months
No 2.5 Referent
Yes 11.2 5.0 3.2 to 7.8
PO 6 MP/Azathioprine in past 12 months
No 3.6 Referent
Yes 11.8 3.6 2.4 to 5.4BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/10
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Despite this survey being conducted only in late 2001,
nearly 6% of Crohn's disease patients reported having
used infliximab. We cannot tell what proportion of these
received the drug initially as part of a clinical trial. Patients
with markers of more severe disease (hospitalizations,
surgery, steroid use) were those most likely to have
received infliximab. Although a survey is clearly not the
appropriate way to measure the effectiveness of an agent,
it is interesting to note that only 20% of those who had
received infliximab rated the current activity of their dis-
ease as inactive or mild and 43% rated it as at least quite
active.
We did find regional variations in prior surgery among UC
patients. It is not possible to exclude selection bias. This
could occur if the probability of remaining a member of
the CCFC after undergoing surgery depended on place of
residence. This is unlikely. It is also possible, though
seemingly unlikely, that regional variations in surgery
could be due to regional variations in post-surgical UC
patients responding to our questionnaire. We did initially
have difficulty in having some patients with prior procto-
colectomy respond to our questionnaire because they
considered themselves to no longer have IBD. We received
many phone calls after the first questionnaire was mailed
out. We contacted each caller to indicate that they should
complete the questionnaire and when we mailed the sec-
ond questionnaire to non-responders we specifically indi-
cated that those UC patients who had previous surgery
should still complete the questionnaire. In the absence of
these two unlikely scenarios, how can one explain the dif-
ferences in the proportion of patients who underwent sur-
gery in different areas of the country? One explanation
could be regional variations in the use of cyclosporine for
acute severe disease and azathioprine for chronically
active disease. However, we could find no evidence of
regional variation in 6 MP/Aza use among UC patients
that had not undergone prior surgery. The number of
patients reporting IV cyclosporine use in the past 12
months (5) precluded any meaningful analysis. Regional
availability of colorectal surgeons could also affect surgi-
cal rates, but this could not be answered with our data.
In conclusion, we have conducted a national survey of
IBD patients. Our sample includes a broader range of
patients that those typical of clinic samples, especially in
terms of patients with less severe disease and UC patients
who have undergone surgery. We have found variations in
the treatment of inflammatory bowel disease in Canada.
Reassuringly, we have not been able to demonstrate sig-
nificant variations in medical treatment based on place of
residence, gender or income levels. Unexplained varia-
tions based on age were seen and should be evaluated fur-
ther in future studies.
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